EPFL BioE Talks SERIES “Swissmedic Innovation Office - Bringing Innovation and Regulation Together“
Event details
| Date | 25.09.2023 |
| Hour | 16:00 › 17:00 |
| Speaker | Philippe Girard, Ph.D., Vice-director and Head of licensing, Swissmedic, the Swiss Agency for Therapeutic Products, Bern (CH) |
| Location | Online |
| Category | Conferences - Seminars |
| Event Language | English |
WEEKLY EPFL BIOE TALKS SERIES
Abstract:
Biomedical research is of central importance for Switzerland. For patients, it is a matter of gaining access as quickly as possible to medicines with a high unmet medical need; for industry and the research sector, it is a matter of creating the best possible framework conditions.
As a regulator, Swissmedic has an important role to play here, ensuring that only high-quality, safe and effective medicines come onto the market in Switzerland and thus protecting patients, but it can also influence the regulatory environment and the way in which researchers and industry work together. In this way, Swissmedic can make research and the conditions for setting up advanced therapies for approval in Switzerland more attractive.
Numerous new approaches and procedures were used during the Covid-19 pandemic. Swissmedic wants to learn lessons from this, and what has proved successful is to be transferred to regular operations. For example, the exchange of information and advice was greatly intensified during this period. In order to perpetuate this development, Swissmedic is planning to set up an Innovation Office to facilitate access to the Institute's regulatory, scientific and technical knowledge and to promote exchange.
Bio:
Education:
1998 – 2001 Doctoral studies in Biotechnology, EPFL, Lausanne (CH); Ph.D.
1995 – 1998 Chemical Engineering training at EPFL (Lausanne, CH) and at the Iowa State University, Ames, IA (USA)
Positions:
Since Aug. 1, 2022 Vice-director, Swissmedic, the Swiss Agency for Therapeutic Products, Bern (CH)
2019 – 2022 Director a.i., Swissmedic, Bern (CH)
Since 2015 Head of Authorisations Dept., Swissmedic, Bern (CH)
2007 – 2015 Head of Laboratory Dept. (Official Medicines Control Laboratory - OMCL), Swissmedic, Bern (CH)
2004 – 2007 Product and Process Development Manager, Debiopharm SA, Lausanne (CH)
2002 – 2004 CTO (Chief Technical Officer), ExcellGene SA, Monthey (CH)
Zoom link (with one-time registration for the whole series) for attending remotely: https://go.epfl.ch/EPFLBioETalks
Instructions for 1st-year Ph.D. students who are under EDBB’s mandatory seminar attendance rule:
IF you are not attending in-person in the room, please make sure to
Abstract:
Biomedical research is of central importance for Switzerland. For patients, it is a matter of gaining access as quickly as possible to medicines with a high unmet medical need; for industry and the research sector, it is a matter of creating the best possible framework conditions.
As a regulator, Swissmedic has an important role to play here, ensuring that only high-quality, safe and effective medicines come onto the market in Switzerland and thus protecting patients, but it can also influence the regulatory environment and the way in which researchers and industry work together. In this way, Swissmedic can make research and the conditions for setting up advanced therapies for approval in Switzerland more attractive.
Numerous new approaches and procedures were used during the Covid-19 pandemic. Swissmedic wants to learn lessons from this, and what has proved successful is to be transferred to regular operations. For example, the exchange of information and advice was greatly intensified during this period. In order to perpetuate this development, Swissmedic is planning to set up an Innovation Office to facilitate access to the Institute's regulatory, scientific and technical knowledge and to promote exchange.
Bio:
Education:
1998 – 2001 Doctoral studies in Biotechnology, EPFL, Lausanne (CH); Ph.D.
1995 – 1998 Chemical Engineering training at EPFL (Lausanne, CH) and at the Iowa State University, Ames, IA (USA)
Positions:
Since Aug. 1, 2022 Vice-director, Swissmedic, the Swiss Agency for Therapeutic Products, Bern (CH)
2019 – 2022 Director a.i., Swissmedic, Bern (CH)
Since 2015 Head of Authorisations Dept., Swissmedic, Bern (CH)
2007 – 2015 Head of Laboratory Dept. (Official Medicines Control Laboratory - OMCL), Swissmedic, Bern (CH)
2004 – 2007 Product and Process Development Manager, Debiopharm SA, Lausanne (CH)
2002 – 2004 CTO (Chief Technical Officer), ExcellGene SA, Monthey (CH)
Zoom link (with one-time registration for the whole series) for attending remotely: https://go.epfl.ch/EPFLBioETalks
Instructions for 1st-year Ph.D. students who are under EDBB’s mandatory seminar attendance rule:
IF you are not attending in-person in the room, please make sure to
- send D. Reinhard a note before noon on seminar day, informing that you plan to attend the talk online, and
- be signed in on Zoom with a recognizable user name (not a pseudonym making it difficult or impossible to be identified).
Practical information
- Informed public
- Registration required
Organizer
- Prof. Li Tang, EPFL
Contact
- Institute of Bioengineering (IBI), Dietrich REINHARD